Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Royal Philips (Koninklijke Philips N.V., NYSE: PHG) is a health technology company whose news flow centers on diagnostic imaging, ultrasound, image-guided therapy, monitoring, enterprise informatics and personal health. Company announcements frequently highlight AI-enabled systems, new product launches and strategic portfolio moves, giving investors and observers insight into how Philips develops and positions its health technology offerings.
Recent Philips news has featured AI-powered innovations in image-guided therapy and diagnostic imaging, such as LumiGuide 3D Device Guidance for light-based navigation during minimally invasive procedures, DeviceGuide for AI-assisted tracking of heart valve repair devices, and Verida, a detector-based spectral CT system with AI integrated across the imaging chain. The company also reports advances in MRI through its BlueSeal Horizon 3.0T platform and extended partnerships in neuroimaging, such as the integration of Cortechs.ai quantitative analytics into Philips MR workflows.
News items also cover enterprise informatics and cloud-based solutions, including the launch of Philips Management 15, a web-based diagnostic viewer that delivers full radiology capabilities through a browser and interfaces with AI tools and interactive reporting. In addition, Philips communicates on long-term partnerships with health systems, monitoring agreements and large-scale deployments of its Azurion image-guided therapy systems.
Corporate and portfolio developments appear regularly in the news stream. Examples include the agreement to acquire SpectraWAVE Inc. to expand intravascular imaging and physiology solutions, and the completed carve-out of the Philips Emergency Care business, which now operates as Heartstream under a Philips brand license. Earnings-related releases and Form 6-K summaries provide context on comparable order intake, sales trends, margins, productivity programs and outlook.
Investors and healthcare professionals following PHG news can use this page to track product introductions, AI and imaging milestones, strategic transactions and quarterly performance updates that shape Philips’ role in global health technology.
Royal Philips (NYSE: PHG) announced the successful pricing of EUR 750 million fixed rate notes due 2027, EUR 650 million Green Innovation Notes due 2029, and EUR 600 million Sustainability Innovation Notes due 2033 under its European Medium Term Note (EMTN) program.
The net proceeds will fund Eligible Projects as per Philips' Green and Sustainability Innovation Bond Framework, with a portion allocated to general corporate purposes. The company plans to optimize its treasury liquidity profile through liability management, including tender offers for outstanding bonds and share buyback programs.
Royal Philips (NYSE: PHG) has entered a multi-year agreement with Prisma Health, South Carolina's largest health system, to enhance patient monitoring and enterprise imaging. This partnership aims to promote interoperability and data analytics, contributing to the Quadruple Aim of healthcare: improving patient and staff satisfaction while lowering costs. Prisma Health, with nearly 3,000 licensed beds and over a million unique patients treated annually, will become the largest North American installation of Philips' Performance Bridge analytics platform for monitoring healthcare delivery.
Royal Philips has initiated a cash tender offer for its outstanding Notes including 71/8% Series A Debentures, 73/4% Series B Debentures, and 7.200% Notes. The offer expires on May 5, 2022, and will allow holders to tender any and all of the specified Notes. Additionally, Philips plans to issue new euro-denominated notes and may redeem existing Euro Notes. The company aims to cancel approximately 28.3 million shares as part of its capital return strategy. Investors should note that the offer is subject to a financing condition.
Summary not available.
Philips reported first-quarter 2022 sales of EUR 3.9 billion, reflecting a 4% decline compared to Q1 2021. The company experienced a significant loss of EUR 152 million from continuing operations, worsening from a loss of EUR 34 million in the previous year. Adjusted EBITA dropped to 6.2% of sales. Despite challenges, including supply chain issues and the Respironics field action, order intake rose by 5%. Notably, Personal Health sales grew by 8%. Philips anticipates further growth in 2022 but acknowledges risks from geopolitical tensions and inflation.
Royal Philips (NYSE: PHG) has announced a notification regarding potential issues with its V60/V60 Plus and V680 ventilators manufactured by its subsidiary, Philips Respironics. The electrical circuit controlling the 35V power supply may cause silent shutdowns, risking respiratory assistance for patients. Philips recommends mitigation actions such as using an oxygen analyzer and ensuring alternative ventilation is available. The FDA has classified the recall as Class 1 in the U.S. Philips is committed to safety and will provide updates by June 30, 2022.
On April 21, 2022, Royal Philips announced the successful use of its CavaClear solution for removing embedded Inferior Vena Cava (IVC) filters in patients, marking the first application of this FDA-cleared technology. The CavaClear system assists in the safe ablation of tissue and removal of IVC filters that may pose long-term health risks. With estimates of over a million patients in the USA at risk from such filters, this innovation aims to improve patient outcomes and procedural efficiency. The device represents a significant advancement in treatment options for complex IVC filter retrieval.
On April 11, 2022, Royal Philips (NYSE: PHG) announced a strategic 10-year partnership with Oulu University Hospital in Finland. This collaboration aims to support the OYS2030 renewal program, which focuses on transforming the hospital's operations and facilities to enhance specialized care for Northern Finland's 750,000 residents. Philips will provide innovative diagnostic and interventional solutions, including 11 advanced interventional suites equipped with the Image Guided Therapy System – Azurion. The agreement also fosters clinical research opportunities and aims to improve operational efficiency and patient experiences.
On April 4, 2022, Philips (NYSE: PHG) presented significant findings at the American College of Cardiology's 71st Annual Scientific Session. A study analyzing Medicare data revealed that around 80% of patients with Cardiac Implantable Electronic Device (CIED) infections are not receiving treatment per established guidelines. The lack of adherence leads to a 32.4% mortality risk post-infection. Timely lead extraction correlates with a 42.9% reduction in death risk. Philips offers a range of Lead Management solutions aimed at improving patient outcomes.
Philips (NYSE: PHG) showcased its integrated solutions for atrial fibrillation at the EHRA 2022 Annual Meeting. Key innovations include the KODEX-EPD system, enhancing RF and cryoballoon therapies with new imaging features. Philips is committed to improving lead management and extraction processes, combating CIED infections effectively. The ePatch monitor streamlines AF diagnosis with extended wear capabilities. Atrial fibrillation, affecting approximately 37 million globally, is projected to double in prevalence over the next 40 years, highlighting the importance of Philips' advancements in cardiac care.